Green Thumb: Canaccord Lowers Price Target After Earnings Missed Estimates

On November 10th, Green Thumb Industries (CSE: GTII) reported its third quarter financial results. The company reported revenues of $233.7 million, an increase of 5.3% increase quarter over quarter but a 48.7% increase year over year. Gross profits meanwhile came in at $129.52 million for the quarter and the firm posted a positive net income of $21.58 million or earnings per share of $0.08. The company indicated that adjusted EBTIDA was $81.2 million, up 2.4% quarter over quarter and 52.6% year over year.

A number of analysts changed their 12-month price targets on Green Thumb, bringing the average 12-month price target to C$58.19 or a 71.5% upside to the current price. Green Thumb currently has 16 analysts covering it, with 4 analysts having a strong buy rating and the other 12 have buy ratings. The street high sits at C$80 from Stifel-GMP while the lowest comes in at C$40.

In Canaccord’s third quarter review they reiterate their buy rating but lowered their 12-month price target to C$53 from C$56, saying, “A clean print amid a slower macro environment.” They additionally believe that the results in the face of a tough backdrop “is a testament to the company’s ability to navigate through sector headwinds while maintaining its profitability profile.”

Altamira Gold Corp. — sponsored Sponsored · Altamira Gold Corp.

For the quarter, Green Thumb slightly missed on all of Canaccord’s estimates, specifically Canaccord forecasted revenues of $234.62 million, adjusted EBITDA of $84.05 million, and earnings per share of $0.10. Canaccord says that this quarter’s outperformance versus its peers is due to closing multiple tack-on acquisitions which included 5 new retail stores.

For the company’s gross margin, Canaccord is very happy with it being flat quarter over quarter as the company saw decelerating revenue.

Below you can see Canaccord’s updated 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fewer Relapses, So Why Expand This Heart Drug Trial? | David Elsley – Cardiol Therapeutics

30X More Chances to Find Gold | Kevin Reid – Arizona Eagle Mining

This Gold Mine Is Worth $2.4 Billion With Just 2 Ounces Per Truckload – Liberty Gold

Recommended

First Majestic Produces 3.4 Million Ounces of Silver in Q3 2026, Jerritt Canyon Restart Remains on Track

Altamira Gold Drills 134 Metres of 0.5 g/t Gold at Maria Bonita, Hole Ends in Mineralization

Related News

Dollarama: Canaccord Maintains $57 Price Target

On September 9, Dollarama Inc (TSX: DOL) reported their fiscal second quarter results for the...

Monday, September 13, 2021, 10:52:00 AM

BMO: Signs Of Optimism Seen Among Precious Metals Investors

Over the last week, BMO has put out a set of notes updating their thoughts...

Tuesday, November 22, 2022, 07:27:00 AM

Magna: Mixed Opinions From Analysts Following Veoneer Announcement

On July 22nd, Magna International (TSX: MG) announced that they would be acquiring Veoneer for...

Saturday, July 31, 2021, 12:09:00 PM

Aurora Cannabis: Analysts Raise Price Targets Following Q1 Results

Yesterday, Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported their first quarter 2021 results. Aurora reported...

Tuesday, November 10, 2020, 03:21:00 PM

Teladoc Sees Consensus Estimates Come Crashing Down After Awful Q1 Results

Last night, Teladoc Health (NYSE: TDOC) confirmed that the pandemic is seemingly over, after seeing...

Thursday, April 28, 2022, 03:41:00 PM